These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
653 related articles for article (PubMed ID: 25761109)
1. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109 [TBL] [Abstract][Full Text] [Related]
2. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511 [TBL] [Abstract][Full Text] [Related]
3. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Alexander M; Mellor JD; McArthur G; Kee D Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899 [TBL] [Abstract][Full Text] [Related]
4. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Danielli R; Ridolfi R; Chiarion-Sileni V; Queirolo P; Testori A; Plummer R; Boitano M; Calabrò L; Rossi CD; Giacomo AM; Ferrucci PF; Ridolfi L; Altomonte M; Miracco C; Balestrazzi A; Maio M Cancer Immunol Immunother; 2012 Jan; 61(1):41-8. PubMed ID: 21833591 [TBL] [Abstract][Full Text] [Related]
5. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057 [TBL] [Abstract][Full Text] [Related]
6. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Di Giacomo AM; Danielli R; Calabrò L; Bertocci E; Nannicini C; Giannarelli D; Balestrazzi A; Vigni F; Riversi V; Miracco C; Biagioli M; Altomonte M; Maio M Cancer Immunol Immunother; 2011 Apr; 60(4):467-77. PubMed ID: 21170646 [TBL] [Abstract][Full Text] [Related]
8. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719 [TBL] [Abstract][Full Text] [Related]
10. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151 [TBL] [Abstract][Full Text] [Related]
11. Ipilimumab activity in advanced uveal melanoma. Khattak MA; Fisher R; Hughes P; Gore M; Larkin J Melanoma Res; 2013 Feb; 23(1):79-81. PubMed ID: 23211837 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424 [TBL] [Abstract][Full Text] [Related]
13. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718 [TBL] [Abstract][Full Text] [Related]
14. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295 [TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. Chiarion Sileni V; Pigozzo J; Ascierto PA; Grimaldi AM; Maio M; Di Guardo L; Marchetti P; de Rosa F; Nuzzo C; Testori A; Cocorocchio E; Bernengo MG; Guida M; Marconcini R; Merelli B; Parmiani G; Rinaldi G; Aglietta M; Grosso M; Queirolo P J Exp Clin Cancer Res; 2014 Apr; 33(1):30. PubMed ID: 24708900 [TBL] [Abstract][Full Text] [Related]
17. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Del Vecchio M; Di Guardo L; Ascierto PA; Grimaldi AM; Sileni VC; Pigozzo J; Ferraresi V; Nuzzo C; Rinaldi G; Testori A; Ferrucci PF; Marchetti P; De Galitiis F; Queirolo P; Tornari E; Marconcini R; Calabrò L; Maio M Eur J Cancer; 2014 Jan; 50(1):121-7. PubMed ID: 24100024 [TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T Melanoma Res; 2015 Aug; 25(4):342-7. PubMed ID: 26050146 [TBL] [Abstract][Full Text] [Related]